In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy
- 1 August 2001
- Vol. 58 (2) , 132-139
- https://doi.org/10.1016/s0090-4295(01)01256-0
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A Tissue-Specific Enhancer of the Prostate-Specific Membrane Antigen Gene, FOLH1Genomics, 2001
- Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancerThe Prostate, 2000
- Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivityInternational Journal of Cancer, 1999
- In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical TrialHuman Gene Therapy, 1999
- DEVELOPMENT OF PROSTATE-SPECIFIC ANTIGEN PROMOTER-BASED GENE THERAPY FOR ANDROGEN-INDEPENDENT HUMAN PROSTATE CANCERJournal of Urology, 1998
- Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administrationGene Therapy, 1998
- Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 1997
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996
- Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate CancerJAMA, 1991
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984